PI
RXRX icon

PFG Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

PFG Investments’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,800
Closed -$52.7K – 1209
2025
Q3 		$52.7K Buy
+10,800
New +$56.7K ﹤0.01% 1083

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

PFG Investments's RXRX Position: Q4 2025 in Review

PFG Investments sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 10,800 shares — an estimated $52.7K sold.

PFG Investments first reported a position in RXRX in Q3 2025 and held it in 1 quarter. The position peaked at $52.7K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • PFG Investments reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PFG Investments sold 10,800 Recursion Pharmaceuticals shares in Q4 2025, an estimated $52.7K.
  • PFG Investments first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PFG Investments's Recursion Pharmaceuticals position peaked at $52.7K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on PFG Investments's 13F filing for Q4 2025, filed 26 Jan 2026.